🎉 M&A multiples are live!
Check it out!

Compass Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Compass Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Compass Therapeutics Overview

About Compass Therapeutics

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.


Founded

2018

HQ

United States of America
Employees

35

Financials

LTM Revenue $0.6M

LTM EBITDA -$61.4M

EV

$118M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Compass Therapeutics Financials

Compass Therapeutics has a last 12-month revenue of $0.6M and a last 12-month EBITDA of -$61.4M.

In the most recent fiscal year, Compass Therapeutics achieved revenue of $0.8M and an EBITDA of -$54.9M.

Compass Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Compass Therapeutics valuation multiples based on analyst estimates

Compass Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $0.8M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$48.5M -$54.9M XXX XXX XXX
EBITDA Margin -Infinity% -6456% XXX XXX XXX
Net Profit -$39.2M -$42.5M XXX XXX XXX
Net Margin -Infinity% -4999% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Compass Therapeutics Stock Performance

As of April 15, 2025, Compass Therapeutics's stock price is $2.

Compass Therapeutics has current market cap of $238M, and EV of $118M.

See Compass Therapeutics trading valuation data

Compass Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$118M $238M XXX XXX XXX XXX $-0.39

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Compass Therapeutics Valuation Multiples

As of April 15, 2025, Compass Therapeutics has market cap of $238M and EV of $118M.

Compass Therapeutics's trades at 186.8x LTM EV/Revenue multiple, and -1.9x LTM EBITDA.

Analysts estimate Compass Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Compass Therapeutics and 10K+ public comps

Compass Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $118M XXX XXX XXX
EV/Revenue 138.5x XXX XXX XXX
EV/EBITDA -2.1x XXX XXX XXX
P/E -4.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -2.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Compass Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Compass Therapeutics Valuation Multiples

Compass Therapeutics's NTM/LTM revenue growth is 1269%

Compass Therapeutics's revenue per employee for the last fiscal year averaged $24K, while opex per employee averaged $1.6M for the same period.

Over next 12 months, Compass Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Compass Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Compass Therapeutics and other 10K+ public comps

Compass Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -6456% XXX XXX XXX XXX
EBITDA Growth 13% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -5186% XXX XXX XXX XXX
Revenue per Employee $24K XXX XXX XXX XXX
Opex per Employee $1.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 1780% XXX XXX XXX XXX
R&D Expenses to Revenue 4981% XXX XXX XXX XXX
Opex to Revenue 6762% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Compass Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Compass Therapeutics M&A and Investment Activity

Compass Therapeutics acquired  XXX companies to date.

Last acquisition by Compass Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Compass Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Compass Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Compass Therapeutics

When was Compass Therapeutics founded? Compass Therapeutics was founded in 2018.
Where is Compass Therapeutics headquartered? Compass Therapeutics is headquartered in United States of America.
How many employees does Compass Therapeutics have? As of today, Compass Therapeutics has 35 employees.
Who is the CEO of Compass Therapeutics? Compass Therapeutics's CEO is Dr. Thomas J. Schuetz, M.D.,PhD.
Is Compass Therapeutics publicy listed? Yes, Compass Therapeutics is a public company listed on NAS.
What is the stock symbol of Compass Therapeutics? Compass Therapeutics trades under CMPX ticker.
When did Compass Therapeutics go public? Compass Therapeutics went public in 2020.
Who are competitors of Compass Therapeutics? Similar companies to Compass Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Compass Therapeutics? Compass Therapeutics's current market cap is $238M
What is the current revenue of Compass Therapeutics? Compass Therapeutics's last 12-month revenue is $0.6M.
What is the current EBITDA of Compass Therapeutics? Compass Therapeutics's last 12-month EBITDA is -$61.4M.
What is the current EV/Revenue multiple of Compass Therapeutics? Current revenue multiple of Compass Therapeutics is 186.8x.
What is the current EV/EBITDA multiple of Compass Therapeutics? Current EBITDA multiple of Compass Therapeutics is -1.9x.
Is Compass Therapeutics profitable? Yes, Compass Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.